Analyst consensus rating
Bicara Therapeutics Analyst Rating: Strong Buy
Direct answer
Bicara Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.50.
Forecast evidence checked October 18, 2026.
Get free Bicara Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.78
- Average price target
- $35.50
- High price target
- $45.00
- Low price target
- $20.00
- Low target gap
- +19.2%
- Target upside
- +111.6%
- High target gap
- +168.2%
- Target range width
- 149%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bicara Therapeutics?
Bicara Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $35.50.
How far are Bicara Therapeutics's low and high targets from the recorded price?
The low target implies +19.2%, while the high target implies +168.2%.
How many analysts are included in Bicara Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Bicara Therapeutics's target upside or downside calculated?
The average target of $35.50 is divided by the recorded price of $16.78, then one is subtracted to produce +111.6%. This does not guarantee a future return.
When was Bicara Therapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.